The board of directors of Simcere Pharmaceutical Group Limited announced that, on January 16, 2023, the New Drug Application of the innovative drug XIANNUOXIN (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged)), which was jointly developed by the Group with Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, has been accepted by the National Medical Products Administration of China under Special Examination and Approval of Drugs. XIANNUOXIN is intended to be used for the treatment of adults infected with mild to moderate COVID-19.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 HKD | -0.88% | +1.63% | -16.49% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.49% | 183.58Cr | |
+25.40% | 4.55TCr | |
+34.52% | 2.45TCr | |
+27.12% | 1.65TCr | |
+21.19% | 1.47TCr | |
+71.91% | 1.43TCr | |
-0.05% | 678.76Cr | |
-11.84% | 673.29Cr | |
+15.08% | 586.92Cr | |
-8.87% | 572.55Cr |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration